Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Jordan F,Hastings ^[1] ; Alvaro,Gonzalez Rajal ^[1] ; Sharissa L,Latham ^[1] ; Jeremy Zr,Han ^[2] ; Rachael A,McCloy ^[1] ; Yolande Ei,O'Donnell ^[1] ; Monica,Phimmachanh ^[1] ; Alexander D,Murphy ^[1] ; Adnan,Nagrial ^[3] ; Dariush,Daneshvar ^[3] ; Venessa,Chin ^[3] ; D Neil,Watkins ^[1] ; Andrew,Burgess ^[2] ; David R,Croucher ^[4]

作者单位： The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia. ^[1] St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia. ^[2] Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia. ^[3] St Vincent's Hospital Sydney, Darlinghurst, Australia. ^[4] Hudson Institute of Medical Research, Victoria, Australia. ^[5] Department of Molecular and Translational Medicine, School of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia. ^[6] Research Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Canada. ^[7] Department of Internal Medicine, Rady Faculty of Health Science, University of Manitoba, Winnipeg, Canada. ^[8] ANZAC Research Institute, Concord, Australia. ^[9] The University of Sydney Concord Clinical School, Faculty of Medicine and Health, Sydney, Australia. ^[10] School of Medicine, University College Dublin, Belfield, Dublin, Ireland. ^[11]

关键词 P70S6K cancer biology chemoresistance human lung adenocarcinoma p53 platinum chemotherapy signalling dynamics